Company Encyclopedia
View More
name
WuXi Biologics
WXXWY.US
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities.
739.76 B
WXXWY.USMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking6/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.80%B
    • Profit Margin20.92%A
    • Gross Margin42.73%B
  • Growth ScoreB
    • Revenue YoY17.76%B
    • Net Profit YoY60.23%B
    • Total Assets YoY9.15%B
    • Net Assets YoY11.37%B
  • Cash ScoreB
    • Cash Flow Margin477.91%C
    • OCF YoY17.76%B
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio18.82%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The Hong Kong stock biotechnology sector collectively weakened, with QYUNS-B and LEADS BIOLABS-B falling over 10%

    The Hong Kong stock biotechnology sector collectively weakened, with QYUNS-B and LEADS BIOLABS-B falling over 10%, while RemeGen, JUNSHI BIO, and WuXi BIO all declined

    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    US
    WXXWY
    -2.91%
    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    US
    WXXWY
    -2.91%

    WuXi accelerating biologics with TrueSite TI

    WuXi Biologics has launched TrueSite TI™, enhancing its biologics development capabilities. The company reported a revenue CAGR of 22.0% from FY 21-24, reaching CNY18.7bn in FY24, with EBITDA growing at 17.3%. WuXi's stock has surged 111.0% over the past year, trading at a P/E of 31.2x. Analysts project a revenue CAGR of 15.4% for FY 24-27, with a positive outlook driven by technological innovation and operational optimization, despite facing competitive and regulatory challenges.

    marketscreener·
    US
    WXXWY
    -2.91%
    HK
    02269
    -3.49%
    marketscreener·
    US
    WXXWY
    -2.91%
    HK
    02269
    -3.49%

    Hong Kong Shares Kick Off Week Higher

    Hong Kong stocks rose 201 points (0.8%) to 26,360, marking three consecutive sessions of gains due to easing China-U.S. trade tensions. Key negotiators reached a consensus, paving the way for a meeting between Presidents Trump and Xi. Chinese industrial profits increased by 3.2% year-on-year in the first nine months of 2025, with a significant 21.6% rise in September. Hong Kong's business sentiment improved to -2 in Q4. All sectors advanced, particularly consumer, tech, and property stocks, with notable early movers including Wuxi Biologics and Prada.

    Trading Economics·
    HK
    02269
    -3.49%
    US
    WXXWY
    -2.91%
    Trading Economics·
    HK
    02269
    -3.49%
    US
    WXXWY
    -2.91%

    Hong Kong stocks in the pharmaceutical outsourcing concept collectively strengthened, JOINN rose over 7%

    As of the time of publication, JOINN is up 7.29%, WuXi AppTec is up 7.06%, WuXi Biologics is up 5.85%, and Pharmaron is up 5.59%

    Zhitong·
    SH
    603127
    -3.30%
    HK
    06127
    -4.36%
    SH
    603259
    -0.89%
    Zhitong·
    SH
    603127
    -3.30%
    HK
    06127
    -4.36%
    SH
    603259
    -0.89%

    WuXi Biologics Hong Kong stock rises 7.2%

    Zhitong·
    US
    WXXWY
    -2.91%
    HK
    02269
    -3.49%
    Zhitong·
    US
    WXXWY
    -2.91%
    HK
    02269
    -3.49%
    Posts
    View More